MyFinsight
Home
Blog
About
ACHIEVE LIFE SCIENCES, INC. (ACHV)
ACHIEVE LIFE SCIENCES, INC. (ACHV)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$19,880K
Free Cash flow
-$10,793K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from public offering, n...
Change in fair value of warrant ...
Warrant issuance cost
Others
Negative Cash Flow Breakdown
Purchase of marketable securitie...
Net loss
Accrued liabilities, other-Nonre...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-74,769
-10,168
-14,662
-14,441
Change in fair value of warrant liability note 5
48,528
-
-
-
Change in fair value of pre-funded warrant liability note 5
-144
-
-
-
Warrant issuance cost
8,799
-
-
-
Depreciation and amortization note 3
58
57
57
54
Stock-based compensation note 7, note 7 and note 7
6,955
-685
1,301
2,340
Shares issued as settlement with trade vendor
-
-
0
-
Accrued interest on svb convertible debt note 8
-
-
0
-
Amortization of 2024 svb convertible term loan transaction costs note 6
11
12
11
13
Change in fair value of contingent consideration note 4 and note 5
100
-285
114
106
Accretion of discount on marketable securities
686
-
-
-
Amortization of premium on securities
12
-
-
-
Prepaid expenses and other assets-Nonrelated Party
-922
-1,625
1,204
-
Prepaid expenses and other assets-Related Party
61
-68
193
-
Accounts payable-Nonrelated Party
-200
-53
-1,091
-
Accounts payable-Related Party
-27
19
8
-
Prepaid expenses and other assets
-
-
-
456
Accrued liabilities, other-Nonrelated Party
-1,252
1,735
25
-
Accounts payable
-
-
-
725
Accrued liabilities, other-Related Party
16
-1
6
-
Accrued liabilities other
-
-
-
583
Accrued clinical liabilities-Nonrelated Party
-48
267
-
-
Accrued clinical liabilities
-
-
-482
-1,120
Accrued clinical liabilities-Related Party
-35
216
-
-
Accrued compensation
756
261
-510
866
Lease obligation
-
-
-1
1
Net cash used in operating activities
-10,777
-6,932
-17,977
-11,331
Proceeds from exercise of warrants
0
21
1,265
120
Proceeds from employee share purchase plan
160
-
0
-
Taxes paid related to net share settlement of equity awards
-
-
0
-
Proceeds from private placement, net of issuance costs note 10-November2022Private Placement
-
-
0
-
Proceeds from registered direct offering, net of issuance costs-February2024Registered Direct Offering
-
-
0
-
Proceeds from june 2025 public offering, net of issuance costs note 7b-June2025Public Offering
-
-
-2
-82
Proceeds from june 2025 public offering exercise of overallotment option, net of issuance costs note 10b
-
-
4,004
-
Proceeds from option exercise
55
-
-
-
Proceeds from june 2025 public offering exercise of overallotment option, net of issuance costs note 7b-June2025Public Offering
-
-
-
4,004
Receipt of 2024 svb convertible term loan second tranche note 6 and note 8
-
-
5,000
-
Proceeds from public offering, net of issuance costs
168,243
-
-
-
Net cash provided by financing activities
168,458
21
6,263
4,042
Purchase of property and equipment
16
-
3
-
Loss on disposal of property and equipment
-
-
1
-
Realized gain on investments
-
-
4
-
Purchase of intangible assets
170
-
-
-
Purchase of investments
-
-
24,755
-
Purchase of marketable securities
138,818
-18,508
-
15,404
Maturities of investments
-
-
30,866
-
Maturities of marketable securities
1,200
-9,634
-
2,750
Net cash provided by (used in) investing activities
-137,804
14,276
709
-12,654
Effect of exchange rate changes on cash
2
-
4
-1
Net increase (decrease) in cash, cash equivalents and restricted cash
19,880
7,364
-11,001
-19,944
Cash, cash equivalents and restricted cash at beginning of the period
28,313
20,949
31,950
12,773
Cash, cash equivalents and restricted cash at end of the period
48,193
28,313
20,949
31,950
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from public
offering, net of issuance...
$168,243K
(308.14%↑ Y/Y)
Proceeds from employee
share purchase plan
$160K
Proceeds from option
exercise
$55K
Net cash provided by
financing activities
$168,458K
(308.66%↑ Y/Y)
Effect of exchange rate
changes on cash
$2K
Net increase
(decrease) in cash, cash...
$19,880K
(-49.18%↓ Y/Y)
Canceled cashflow
$148,581K
Maturities of marketable
securities
$1,200K
(-94.62%↓ Y/Y)
Change in fair value of
warrant liability note 5
$48,528K
Warrant issuance cost
$8,799K
Stock-based compensation
note 7, note 7 and note...
$6,955K
(35.84%↑ Y/Y)
Prepaid expenses and
other...
-$922K
Accrued compensation
$756K
(151.64%↑ Y/Y)
Change in fair value of
pre-funded warrant...
-$144K
Change in fair value of
contingent consideration...
$100K
(-46.81%↓ Y/Y)
Depreciation and
amortization note 3
$58K
(-50.43%↓ Y/Y)
Accrued liabilities,
other-Related Party
$16K
Amortization of premium on
securities
$12K
Amortization of 2024 svb
convertible term loan...
$11K
(-60.71%↓ Y/Y)
Net cash provided by
(used in) investing...
-$137,804K
(-863.20%↓ Y/Y)
Net cash used in
operating activities
-$10,777K
(46.53%↑ Y/Y)
Canceled cashflow
$1,200K
Canceled cashflow
$66,301K
Purchase of marketable
securities
$138,818K
(3158.64%↑ Y/Y)
Net loss
-$74,769K
(-192.70%↓ Y/Y)
Purchase of intangible
assets
$170K
Purchase of property and
equipment
$16K
Accrued liabilities,
other-Nonrelated Party
-$1,252K
Accretion of discount on
marketable securities
$686K
Accounts
payable-Nonrelated Party
-$200K
Prepaid expenses and
other assets-Related...
$61K
Accrued clinical
liabilities-Nonrelated Party
-$48K
Accrued clinical
liabilities-Related Party
-$35K
Accounts
payable-Related Party
-$27K
Buy us a coffee